Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Budde LE, Kamdar M, Assouline SE, Chavez JC, et al. Blood 2026;148:682-692.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Budde LE, Kamdar M, Assouline SE, Chavez JC, et al. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood 2026;148:682-692.
PMID: 42013019